COVID-19

Outside of the loss of human life due to the COVID-19 pandemic, the past two years have greatly affected hospitals, health systems and the way providers deliver care. Healthcare executives are grappling with federal monetary assistance, growing burnout rates, workforce shortages and federal oversight of vaccines and testing. This channel is also designed to update clinicians on new research and guidelines regarding COVID patient treatment strategies and risk assessments.

RSS icon
Thumbnail

CMS forms independent commission for COVID-19 response in nursing homes

CMS has announced the members of the independent Coronavirus Commission on Safety and Quality in Nursing Homes, as the agency is seeking an independent review and assessment of what happened at nursing homes across the countries when COVID-19 hit.

Thumbnail

Hospitals are already treating COVID-19 patients with common steroid

Hospitals in the U.S. are already using dexamethasone, a commonly known steroid that’s readily available and inexpensive, to treat COVID-19 patients without waiting for confirmation of preliminary results from a British study that found the drug can greatly improve survival.

Significant portion of COVID-19 may be asymptomatic

Between 40% and 45% of COVID-19 infections could be in people who display no symptoms of the illness, according to an analysis by Scripps Research published in Annals of Internal Medicine.

Thumbnail

Cleveland Clinic develops first risk prediction model for COVID-19 patients

Researchers at Cleveland Clinic have created the first risk prediction model that allows healthcare providers to find the likelihood of an individual patient testing positive for COVID—19, as well as possible outcomes from the virus.

Thumbnail

First drug found to improve COVID-19 survival

A commonly known steroid drug has been found to greatly improve survival for COVID-19 patients. In fact, among severe patients, the steroid, Dexamethasone, reduced the number of deaths by one-third in a study conducted by the University of Oxford.

FDA says hydroxychloroquine unlikely to be effective in treating COVID-19

The FDA has revoked its emergency use authorization for hydroxychloroquine as a treatment for COVID-19 hospital patients, determining that the controversial drug was “unlikely to be effective in treating COVID-19.”

Thumbnail

HHS will distribute another $35B in COVID-19 relief to healthcare companies

HHS is distributing another $35 billion from the CARES Act designated for healthcare providers responding to the crisis. The CARES Act allocated $175 billion in relief funds to hospitals and healthcare providers, especially those majorly affected by the pandemic.

Thumbnail

HHS increases reporting requirements for COVID-19 testing

HHS has announced new laboratory data reporting guidance for COVID-19 testing, expanding requirements for laboratories to report demographic details that can help improve the public response.

Displaying 353 - 360 of 403

Around the web

Cardiovascular Business
Q&A: MedAxiom CEO explores key trends in cardiologist, cardiovascular surgeon compensation

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

Cardiovascular Business
Payment cuts and beyond: Key takeaways for cardiologists from the 2025 Medicare Physician Fee Schedule

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

AI in Healthcare
A modest proposal to rally AI regulators around a simple game plan

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”